Ask AI

Winter 2026 Genitourinary Onc Events

 
Virtual Simulcast
 
In-Person
 
Free CME Credits

Winter 2026 Genitourinary Onc Events

Advance your expertise in genitourinary oncology with a curated series of events focused on the latest therapeutic advances in bladder and prostate cancer. Learn from leading experts as they explore evolving treatment strategies in advanced bladder cancer, practical applications of PARP inhibitors in prostate cancer, and emerging HER2-targeted therapies shaping care for HER2-positive advanced bladder cancer.

All events are CME-certified and complimentary to attend. Register today!

 

Dates February 26 - 27, 2026

 

Time Varies per Event
Timezone Converter ›

 

Location San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103

Event Schedule

Attend in-person or via virtual simulcast.

Featured Faculty

Faculty

Wassim Abida, MD, PhD

  • Director of Translational Research, Prostate Cancer
  • Associate Member, Genitourinary Oncology Service
  • Memorial Sloan Kettering Cancer Center
  • Associate Professor of Medicine
  • Weill Cornell Medical College
  • New York, New York
Faculty

Neeraj Agarwal, MD, FASCO

  • Professor of Medicine
  • Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
  • HCI Presidential Endowed Chair of Cancer Research
  • Director, Center of Investigational Therapeutics
  • Director, Genitourinary Oncology Program
  • Huntsman Cancer Institute, University of Utah (NCI-CCC)
  • Salt Lake City, Utah
Faculty

Fed Ghali, MD

  • Assistant Professor
  • Department of Urology
  • Yale Cancer Center
  • Yale School of Medicine
  • New Haven, Connecticut
Faculty

Petros Grivas, MD, PhD

  • Professor, Division of Hematology Oncology
  • Department of Medicine
  • Medical Director, International Program
  • Medical Director, Local/Regional Outreach
  • University of Washington
  • Professor, Clinical Research Division
  • Fred Hutchinson Cancer Center
  • Seattle, Washington
Faculty

Shilpa Gupta, MD

  • Professor of Medicine
  • Cleveland Clinic Lerner College of Medicine at Case Comprehensive Cancer Center
  • Director, Genitourinary Oncology Program
  • Cleveland Clinic Taussig Cancer Institute
  • Cleveland, Ohio
Faculty

Vadim S. Koshkin, MD

  • Associate Professor of Clinical Medicine
  • Division of Hematology/Oncology
  • Department of Medicine
  • Helen Diller Family Comprehensive Cancer Center
  • University of California, San Francisco
  • San Francisco, California
Faculty

Daniel P. Petrylak, MD

  • Professor of Medicine and Urology
  • Director, Genitourinary Oncology Research Program
  • Yale Comprehensive Cancer Center
  • Yale School of Medicine
  • New Haven, Connecticut

Accreditation

Ascending to Higher Heights in the Treatment of Locally Advanced/Metastatic Bladder Cancer—Expert Insights on Navigating the Latest Guidelines and Therapeutic Advances

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Accreditation

Precision in Practice: A Master Class on PARPi Combinations, Testing Strategies, and Toxicity Management in Metastatic Prostate Cancer

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this Application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-015-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.

Accreditation

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

JOINT ACCREDITATION INTERPROFESSIONAL CONTINUING EDUCATION

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

San Francisco Marriott Marquis

780 Mission Street
San Francisco, CA 94103

Not an official event of the 2026 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Ascending to Higher Heights in the Treatment of Locally Advanced/Metastatic Bladder Cancer—Expert Insights on Navigating the Latest Guidelines and Therapeutic Advances
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by an educational grant from Pfizer Inc. and Astellas Inc.

Precision in Practice: A Master Class on PARPi Combinations, Testing Strategies, and Toxicity Management in Metastatic Prostate Cancer
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.
Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.